Muscle Spasms

Dysport Indication Expanded to Include Upper Limb Spasticity Treatment in Children

The Food and Drug Administration (FDA) has expanded the indication of Dysport (abobotulinumtoxinA; Ipsen) to include the treatment of upper limb spasticity in patients aged 2 years and older, excluding spasticity caused by cerebral palsy. Previously, Dysport was only approved to treat lower limb spasticity in patients aged 2 years and older.  The approval was…

Myobloc Approved for the Treatment of Chronic Sialorrhea

The Food and Drug Administration (FDA) has approved Myobloc (rimabotulinumtoxinB injection; US WorldMeds) for the treatment of chronic sialorrhea in adults. The approval was based on multiple studies, including a double-blind, placebo-controlled trial, followed by an open-label treatment period, in 187 patients with chronic, troublesome sialorrhea for at least 3 months. Patients were randomized to…